NCT07535242Completed
Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS
Investigation of the Relationship Between Serum GFAP, NfL, and VEGF Levels and Clinical Progression Markers in Progressive Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 22 (actual)
- First submitted
- 3 Apr 2026
- Start date
- 21 Apr 2026
- Primary completion date
- 30 Apr 2026
- Lead sponsor
- Ondokuz Mayıs University
- Diseases
- Multiple sclerosis
- NCT number
- NCT07535242
What you commit to
- Study type: Observational
- Participants enrolled: 22
- From 21 Apr 2026 to the primary completion date, 30 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Change in medication within the last 3 months
Other illness
- Presence of another neurological disorder
Other
- Relapse within the last 3 months
Who the study is looking for
- Confirmed diagnosis of MS
- Progressive type MS
- Voluntary participation
- Age between 18-60 years
- Cooperative
- EDSS score ≥ 5.5
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ondokuz Mayis University Coordinator of this site? Confirm its status | Samsun | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.